April 2009 Blog Questions on Saxagliptin

In your opinion, how is emergence of a new DPP-4 inhibitor (saxagliptin) influencing care of patients with type 2 diabetes?

Do you view these changes as positive?


If approved, what role do you predict saxagliptin will have in managing patients with type 2 diabetes?

March 2009 PCMG Blog Question

How have the results of VADT and ACCORD changed the way you manage your patients with type 2 diabetes?

December PCMG Blog Questions on JUPITER

• Do you normally obtain hs-CRP levels on your asymptomatic patients with normal LDL-cholesterol levels?
  
• Do you plan to switch any of your patients from their current statin therapy to rosuvastatin? If so, why?
  
• What other cardiovascular inflammatory markers are you currently screening for in your intermediate and high risk patient populations?
  
• How are the pharmaceutical representatives in your area for Merck and Pfizer handling the news about JUPITER?
  
• Are any of your patients coming to you and specifically asking you, as their physician, to place them on Crestor, based upon the results of JUPITER?

Neuroinflammation and Chronic Pain

Please share any interesting patients who may experience neuroinflammation with our membership. These are complicated pain management issues. We encourage other members to offer their expertise and pain management strategies.

Vitamin D Deficiency

Are you obtaining serum vitamin D levels routinely in your patients with cardiovascular disease, osteoporosis and diabetes?

Are you advising patients at high risk for CVD to spend at least 15 minutes daily outside exposed to sunlight?

What are your views on the ACCORD and ADVANCE trials?

Have any of you observed any unusual cases of insulin reactions such as lipoatrophy?
How do they affect your patient’s glycemic control?
What tricks do you use to determine the cause of the insulin reactions?
How do you counsel them on altering their injection behaviors?